Canada just became the first G7 country to approve a generic weight-loss drug. That’s a big deal.
For the past few years, supply and demand created real friction in this space — but it rarely stopped determined patients from accessing these medications. Efficacy was never really the question. Affordability was. That’s changing now, and it’s a win on two fronts: for people who need access, and for plan sponsors managing costs.
Brand-name Ozempic runs $200 to $450 a month. The first generic is estimated at $40 to $80. Health Canada approved Dr. Reddy’s generic semaglutide — the active ingredient in both Ozempic and Wegovy — with eight more generics currently under review. Under the pan-Canadian pricing framework, that kind of drop is exactly what you’d expect from a first-to-market generic.
So costs get better. But is that the whole story? Probably not. Lower prices and broader access will almost certainly drive higher utilization — and plan sponsors will need to think carefully about plan design, eligibility criteria, and how these drugs are positioned alongside other treatments. The cost conversation and the plan design conversation need to happen together.
The backdrop is hard to ignore. Nearly one in three Canadians lives with obesity. The condition costs Canada up to $54 billion a year in healthcare spending and lost productivity. Demand is only going in one direction.
Add a full-on pricing war between Eli Lilly and Novo Nordisk, new oral options entering the market, and a projected global market of US$150 billion within a decade, and this space is moving fast.
At Matheis Financial Group, these are exactly the kinds of conversations we’re having with employers as they evaluate the future of their benefits plans and Total Rewards strategies. With this space evolving so quickly, now is the time to revisit the GLP-1 conversation within employer-sponsored plans — and we’d be happy to discuss what this could mean for your organization specifically.